Summary Epidermal growth factor receptor (EGFR) content was determined by a radioligand receptor assay in 140 primary laryngeal squamous cell carcinomas (median value of 8.4 fmol mg-1 protein, range 0-169.9 fmol mg-protein). Cox univariate regression analysis using EGFR as a continuous variable showed that EGFR levels are directly associated with the risk of death (X2 = 14.56, P-value = 0.0001) and relapse (x2 = 7.77, P-value = 0.0053). A significant relationship between EGFR status and survival was observed at the different arbitrary cut-off values chosen (8, 16 and 20 fmol mg-1 protein). The cut-off value of 20 fmol mg-' protein was the best prognostic discriminator. In fact, the 5 year survival was 81% for patients with EGFRtumours compared with 25% for patients with EGFR+ tumours (P<0.0001). The 5 year relapse-free survival was 77% for patients with EGFR-tumours compared with 24% for patients with EGFR+ tumours (P <0.010). When clinicopathological parameters and EGFR status were examined in the multivariate analysis, T classification and EGFR status retained an independent prognostic value. In this study we demonstrated that high EGFR levels single out patients with poor prognosis in laryngeal cancer.
Laryngeal cancer accounts for 1.2% of all new cases of malignancy in the United States (Silverberg et al., 1990) with an incidence of 12 300 cases per year, and accounts for 0.7% of all cancer deaths.
At present, therapy is determined by age, performance status, stage of disease and tumour location. However, these clinical parameters are still inadequate for the prognostic characterisation of laryngeal cancer, since patients with identical clinicopathological features may differ widely in the development of the disease and in response to therapy (Snow, 1989) . Thus, the identification of factors more strictly related to tumour cell biology may be useful in characterising patients with a different prognosis. Previous studies have identified biological factors, such as DNA index and/or ploidy (Rua et al., 1991; Kearseley et al., 1991) , or cell proliferation markers (Coltrera, 1993) , which may predict the clinical outcome of laryngeal cancer. Moreover, much attention has been focused on the role of oncogenes, i.e. p53, c-ras, c-myc (Brennan et al., 1995; Anderson et al., 1992; Scambia et al., 1994a; Irish and Bernstein, 1993) and EGFR expression and/or amplification (Irish and Bernstein, 1993; Miyaguchi et al., 1990; Scambia et al., 1991; Santini et al., 1991) .
The epidermal growth factor/epidermal growth factor receptor (EGF/EGFR) system may be involved in cell transformation through different mechanisms, the most frequent of which are autocrine overproduction of epidermal growth factor/transforming growth factor alpha (EGF/ TGFa) and overexpression of normal EGFR (by gene amplification or altered transcriptional mechanisms) (Velu, 1990) . Tumours containing high EGFR levels appear to have a worse prognosis in breast (Sainsbury et al., 1987) , ovarian , endometrial (Scambia et al., 1994b ), bladder (Neal et al., 1991 and oesophageal (Ozawa et al., 1989) cancer.
Although the role of EGFR in the development of the malignant laryngeal squamous cell phenotype has been described (Grandis and Tweardy, 1993; Stanton et al., 1994) , the prognostic role of EGFR in laryngeal tumours is not fully established. A previous study (Dassonville et al., 1993) reported an independent prognostic role of high EGFR levels in a series of head and neck cancers. In our preliminary study, despite the relatively small number of laryngeal tumours examined and the short follow-up time, EGFR levels are associated with a more aggressive laryngeal cancer behaviour (Maurizi et al., 1992) . In this study the clinical significance of EGFR in laryngeal squamous cell carcinoma was investigated for the first time on a large single institution patient population with a long follow-up.
Materials and methods
Our study included 140 primary laryngeal cancer patients admitted to the Department of Otolaryngology of the Catholic University of Rome. All patients were staged according to TNM classification (Hermanek and Sobin, 1992) and tumours graded as well (GI), moderately (G2) and poorly (G3) differentiated. The clinicopathological features of the patients are listed in Table I .
Tumours were classified as supraglottic, glottic or transglottic when the extent of disease did not permit identification of the original site.
Seventy-three patients underwent radical laryngectomy and sixty-seven had conservative surgery (i.e. cordectomy, horizontal supraglottic laryngectomy and hemilaryngectomy). None of the patients received preoperative chemotherapy or radiotherapy. All the patients with relapse or regional neck metastasis underwent salvage surgery or irradiation.
EGFR assay Tissue specimens were frozen on dry ice shortly after surgical removal and stored at -80°C until processed. A representative section of specimens was retained for histological examination, which revealed that most of the cells were cancer cells.
The membrane fraction and cytosol were prepared as described elsewhere (lacobelli et al., 1987; (Scambia et al., 1991) . Kaplan and Meier (1958) and the curves were examined by means of the log-rank test (Mantel, 1966) . Multivariate analysis was performed by the Cox proportional hazards model (Cox, 1972 EGFR+ tumours (P<0.010). T classification was also significantly correlated with survival in the univariate analysis (Table II) . Table III shows the multivariate analysis of prognostic variables for survival in laryngeal cancer patients. T classification and EGFR status are the most important independent prognostic factors in overall and relapse-free survival. Moreover, in overall survival, histopathological grading seems to have an additional role as a prognostic factor. (Scambia et al., 1991) in accordance with other authors (Santini et al., 1991) . A significant correlation between EGFR levels and stage was found in head and neck cancer (Santini et al., 1991; Dassonville et al., 1993 ), whereas we reported higher EGFR expression in poorly differentiated (G3) than in well/moderately differentiated (G1-G2) laryngeal tumours (Scambia et al., 1991) . To our knowledge, this is the first study analysing the prognostic sigificnce of EGFR in a large prospective series of laryngeal squamous cell carcinomas with a long follow-up period. In our series the presence of high EGFR levels is significantly correlated with a poor overall and relapse-free survival. Moreover, analysis of logarithmically transformed EGFR values shows that the risk of death and relapse increases with increasing EGFR values in a significant way.
In the multivariate analysis, EGFR status retained an independent prognostic role, suggesting that EGFR assessment, together with clinical parameters, such as stage of disease, may improve the prognostic characterisation of laryngeal cancer patients. Our data are in accordance with those of Dassonville et al. (1993) who reported a prognostic role for EGFR in head and neck tumours, and with our preliminary results on a smaller series of laryngeal cancer (Maurizi et al., 1992) .
This study suggests that the assessment of EGFR status at the time of initial surgery may identify a subset of patients with a particularly poor prognosis and permit therapy to be modified accordingly. What is more, the prognostic significance of EGFR levels might imply that laryngeal cancer is a candidate for a novel anti-cancer therapy based on drugs targeted directly against EGFR activity, such as anti-EGFR monoclonal antibodies and the specific inhibitor of the EGFR tyrosine kinase, which inhibit the growth of cancer ceRls in vitro and in vivo Schnurch et al., 1994; Fry et al., 1994) .
